Bioxyne (ASX: BXN) is on track to release data from the Phase IIb trial on the company’s chronic obstructive pulmonary disease (COPD) therapy in June.
Data from the 320 patient study into the efficacy and safety of HI-164OV therapy is in the late stages analysis.
The study aimed to assess the impact of treatment with HI-164OV in reducing severe exacerbations in COPD and reducing the need for admission to hospital.
Primarily the company hopes that data from the study will demonstrate a reduction in exacerbations requiring oral corticosteroid treatment or hospitalisation.
The secondary endpoints of the study are to determine whether HI-164OV can reduce the severity of exacerbations, the number of patients requiring corticosteroid treatments or hospitalisation and the use of antibiotics or corticosteroids.
Importantly, there have been no indications of patient-related safety issues during the trial.
A number of measures of disease severity are being measured to determine the profile and benefits of the therapy.
Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.